[go: up one dir, main page]

SG10201709765SA - Breast Cancer Therapeutic Agent Containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as Active Ingredient - Google Patents

Breast Cancer Therapeutic Agent Containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as Active Ingredient

Info

Publication number
SG10201709765SA
SG10201709765SA SG10201709765SA SG10201709765SA SG10201709765SA SG 10201709765S A SG10201709765S A SG 10201709765SA SG 10201709765S A SG10201709765S A SG 10201709765SA SG 10201709765S A SG10201709765S A SG 10201709765SA SG 10201709765S A SG10201709765S A SG 10201709765SA
Authority
SG
Singapore
Prior art keywords
breast cancer
indirubin
oxime
nitro
hydroxy
Prior art date
Application number
SG10201709765SA
Inventor
Il Kim Jae
KIM Seon-Myung
Ho KIM San
Young Park Moon
Original Assignee
Anygen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anygen Co Ltd filed Critical Anygen Co Ltd
Publication of SG10201709765SA publication Critical patent/SG10201709765SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient A breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient has been disclosed. Further, a breast cancer therapeutic agent containing 5'- hydroxy-5-nitro-indirubin-3'-oxime as cyclin-dependent kinase (CDK) inhibitor, wherein said breast cancer is triple negative breast cancer (TNBC) and/or an estrogen receptor (ER) positive breast cancer including the tamoxifen-resistant estrogen receptor (ER) positive breast cancer has been disclosed. Figure 1
SG10201709765SA 2016-11-25 2017-11-24 Breast Cancer Therapeutic Agent Containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as Active Ingredient SG10201709765SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160157929A KR101819544B1 (en) 2016-11-25 2016-11-25 Breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient

Publications (1)

Publication Number Publication Date
SG10201709765SA true SG10201709765SA (en) 2018-06-28

Family

ID=58709857

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201709765SA SG10201709765SA (en) 2016-11-25 2017-11-24 Breast Cancer Therapeutic Agent Containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as Active Ingredient

Country Status (6)

Country Link
US (1) US10285979B2 (en)
EP (1) EP3327015B1 (en)
JP (1) JP6445082B2 (en)
KR (1) KR101819544B1 (en)
ES (1) ES2774485T3 (en)
SG (1) SG10201709765SA (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7029345B2 (en) * 2018-04-25 2022-03-03 株式会社三共 Pachinko machine
RU2680603C1 (en) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Application of 3-o-sulfamate-16,16-dimethyl-d-homoequilinine for treatment of oncological diseases
KR102784482B1 (en) * 2019-11-04 2025-03-21 주식회사 씨케이리제온 Compositions and methods for inhibiting and/or treating neurodegenerative diseases and/or clinical conditions thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100588803B1 (en) * 2004-01-27 2006-06-12 학교법인조선대학교 Indirubin derivatives with anticancer activity in cancer cell lines
EP1963264A2 (en) * 2005-12-23 2008-09-03 Centre National De La Recherche Scientifique (Cnrs) New 3 -, 7-substituted indirubins and their applications
KR101180030B1 (en) * 2010-02-05 2012-09-05 광주과학기술원 Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors with anti-cancer activity
EP2827869A4 (en) * 2012-03-23 2015-09-23 Dennis Brown COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO

Also Published As

Publication number Publication date
JP6445082B2 (en) 2018-12-26
US10285979B2 (en) 2019-05-14
JP2018083801A (en) 2018-05-31
ES2774485T3 (en) 2020-07-21
EP3327015A1 (en) 2018-05-30
KR101819544B1 (en) 2018-01-17
US20180147182A1 (en) 2018-05-31
EP3327015B1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
MX2020014245A (en) Inhibitors of cyclin-dependent kinases.
ZA202107579B (en) Pharmaceutical combinations for the treatment of cancer
NZ754865A (en) Combination therapy for the treatment of cancer
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
ZA201902053B (en) Pharmaceutical composition
MY196243A (en) Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
EP3677584A4 (en) Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
TN2019000210A1 (en) Antitumoral compounds
SA519402288B1 (en) Pyrimidine compound and pharmaceutical use thereof
PH12020550491A1 (en) Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
PH12019502676A1 (en) Moisturizing topical preparation
MX2019011116A (en) Bruton's tyrosine kinase inhibitors.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2021010022A (en) Pharmaceutical composition.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
EA201792595A1 (en) CONTRACEPTIVE MEANS BASED ON DROSPYRENON FOR A PATIENT SUFFERING AN EXCESSIVE BODY MASS
SG10201709765SA (en) Breast Cancer Therapeutic Agent Containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as Active Ingredient
MX2022007265A (en) Compounds active towards nuclear receptors.
MX2020005659A (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer.
MX2019010981A (en) Combination therapies for the treatment of breast cancer.
EP4265298A3 (en) Salt
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression